Incyte (NASDAQ: INCY) buys Vega Therapeutics in $1.25B bleeding-disorder bet
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Incyte Corporation has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC, for an upfront payment of $1.25 billion. Star Therapeutics may receive up to an additional $750 million in sales milestone payments. The deal adds VGA039, an investigational monoclonal antibody in Phase 3 development for von Willebrand disease, to Incyte’s hematology portfolio and late-stage pipeline. VGA039 is being developed as a once-monthly subcutaneous prophylactic therapy and has received multiple U.S. FDA designations, including Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease. Incyte expects to record the transaction as a one-time R&D expense in its third-quarter and full-year 2026 GAAP and non-GAAP results.
Positive
- Strategic late-stage asset added: Incyte acquired Vega Therapeutics, securing VGA039, a Phase 3 monoclonal antibody for von Willebrand disease with multiple FDA designations, potentially strengthening its hematology portfolio and late-stage pipeline.
Negative
- Large one-time R&D expense: The $1.25 billion upfront consideration is expected to be recorded as a one-time R&D expense in Incyte’s third-quarter and full-year 2026 GAAP and non-GAAP results, which may weigh on reported earnings for those periods.
Insights
Incyte is making a large R&D bet to expand into bleeding disorders with a late-stage asset.
The acquisition of Vega Therapeutics for an upfront $1.25 billion, plus up to $750 million in sales milestones, gives Incyte control of VGA039, a Phase 3 monoclonal antibody for von Willebrand disease. VGA039 fits Incyte’s hematology focus and targets a sizeable diagnosed U.S. population of about 135,000 patients.
VGA039 already holds Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the FDA, which can support an efficient development and review path if Phase 3 data are supportive. However, the program is still investigational, and outcomes depend on successful completion of the pivotal VIVID-6 study across all VWD types.
The entire upfront consideration is expected to be recorded as a one-time R&D expense in Incyte’s Q3 and full-year 2026 GAAP and non-GAAP results, which may create a notable accounting impact on reported earnings for those periods. Future disclosures on VIVID-6 progress and regulatory interactions will be important for understanding how this transaction translates into potential long-term revenue.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Upfront acquisition price: $1.25 billion
Potential milestone payments: $750 million
VWD diagnosed population US: 135,000 people
+3 more
6 metrics
Upfront acquisition price
$1.25 billion
Cash consideration to acquire all outstanding shares of Vega Therapeutics
Potential milestone payments
$750 million
Additional sales milestones payable to Star Therapeutics
VWD diagnosed population US
135,000 people
Approximate number of von Willebrand disease patients in the United States
FDA designations for VGA039
4 designations
Breakthrough Therapy, Fast Track, orphan drug, rare pediatric disease
Development stage of VGA039
Phase 3
Pivotal VIVID-6 study in von Willebrand disease prophylaxis
Accounting treatment
One-time R&D expense
To be reflected in Q3 and full-year 2026 GAAP and non-GAAP results
Key Terms
monoclonal antibody, von Willebrand disease, Breakthrough Therapy, orphan drug, +2 more
6 terms
monoclonal antibody medical
"The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
von Willebrand disease medical
"VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD)"
A genetic bleeding disorder caused by a shortage or malfunction of a protein that helps blood clot, so people bruise easily, bleed longer from cuts, or have heavy menstrual bleeding. It matters to investors because the condition drives demand for diagnostics, replacement therapies, and new treatments; changes in prevalence, clinical trial results, regulatory approvals, or reimbursement can directly affect companies working in blood disorders and related healthcare markets.
Breakthrough Therapy regulatory
"VGA039 has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations"
A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.
orphan drug regulatory
"VGA039 has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations"
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
rare pediatric disease regulatory
"VGA039 has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration"
A rare pediatric disease is a serious medical condition that primarily affects children and occurs so infrequently that only a small number of patients exist. Investors care because treatments for such conditions often get special regulatory incentives—think of government fast lanes and rewards for developers—making smaller markets potentially profitable due to pricing power, shorter development timelines, and reduced competition, much like a niche product that receives government-backed advantages.
Phase 3 VIVID-6 study medical
"VGA039 has advanced into the Phase 3 VIVID-6 study (NCT07115004), a global single arm cross-over study"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 6, 2026
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | ||||
(302 ) 498-6700
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 (§ 240.12b—2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01 Other Events.
On July 6, 2026, Incyte Corporation (the “Company”) issued a press release announcing it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC (“Vega Therapeutics”). A copy of the Company’s press release announcing the completion of its acquisition of Vega Therapeutics is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
| Exhibits | Description | |||||||
| 99.1 | Press release issued by Incyte Corporation dated July 6, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 6, 2026 | ||||||||
| INCYTE CORPORATION | ||||||||
| By: | /s/ Richard Hoffman | |||||||
| Richard Hoffman | ||||||||
| Executive Vice President and General Counsel | ||||||||
3
Exhibit 99.1
FOR IMMEDIATE RELEASE
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Acquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte’s late-stage pipeline
WILMINGTON, Del. – July 6, 2026 – Incyte (Nasdaq:INCY) announced today it has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder, to Incyte’s hematology portfolio.
“With the acquisition complete, VGA039 adds one of the most promising late-stage hematology assets in development to our portfolio. As a potential first-in-class therapy, VGA039 is a strong strategic fit with our hematology franchise and expands our presence into bleeding disorders,” said Bill Meury, Chief Executive Officer of Incyte. “Our priority is to advance the Phase 3 program, and we look forward to partnering with our talented new colleagues from Vega to progress VGA039 through clinical development.”
VGA039 modulates Protein S to improve hemostasis, potentially improving the body’s ability to control bleeding in numerous bleeding disorders. VGA039 is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, VGA039 has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, who currently require frequent intravenous infusions.
VGA039 has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration (FDA). VGA039 has advanced into the Phase 3 VIVID-6 study (NCT07115004), a global single arm cross-over study to investigate safety and efficacy of the subcutaneous administration of VGA039 as prophylaxis for bleeding in patients with every type of VWD, including those with a high disease burden.
As previously disclosed, under the terms of the parties’ stock purchase agreement, Incyte has acquired all outstanding shares of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones. We expect the transaction to be reflected as a one-time R&D expense in the third quarter and full year 2026 GAAP and non-GAAP financial results.
Lazard acted as financial advisor to Incyte, and Goodwin Procter LLP served as its legal counsel on the transaction. Evercore and Morgan Stanley acted as financial advisors to Star Therapeutics, and Fenwick & West LLP served as its legal counsel.
About VGA039
VGA039 is an investigational monoclonal antibody therapy with a novel mechanism of action that targets Protein S, with dual actions promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. VGA039 has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with all types of von Willebrand disease (VWD) and bleeding sites. As a subcutaneously self-administered investigational antibody therapy with a convenient once monthly dosing regimen, VGA039 has the potential to improve convenience and quality of life for patients.
About von Willebrand Disease
Von Willebrand disease (VWD) is the most common inherited bleeding disorder in which the blood does not clot properly, caused by low or defective von Willebrand factor (VWF). VWD patients may experience excessive bleeding with varying severity and frequency, negatively impacting their daily lives. Current therapies for VWD prophylaxis include factor replacement therapies requiring multiple intravenous (IV) infusions every week. Approximately 135,000 people in the United States have been diagnosed with von Willebrand disease.1
About Incyte®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.
To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.
Incyte Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the anticipated benefits of the Vega Therapeutics acquisition; costs and other anticipated financial impacts of the acquisition; expectations regarding VGA039’s clinical development and its potential to strengthen Incyte’s late-stage pipeline, expand Incyte’s presence in bleeding disorders and become an important new growth driver for Incyte’s hematology portfolio; the potential and promise VGA039 offers patients with bleeding disorders, including the potential to be the first subcutaneous prophylactic therapy with a convenient dosing regimen for patients with VWD, and its ability to address significant unmet need; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”
Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including unexpected costs, charges or expenses resulting from the acquisition; the risk that Incyte may not be able to successfully integrate the business of Vega Therapeutics and realize the expected benefits of the acquisition in a timely manner or at all; the sufficiency of clinical trial data for VGA039, as well as Incyte’s other products and product candidates, to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Incyte’s ability to achieve commercial success for VGA039, if approved; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.
# # #
Contacts
| Media | Investors | ||||||||||
| media@incyte.com | ir@incyte.com | ||||||||||
1. Data on File.
2
FAQ
What did Incyte (INCY) announce regarding Vega Therapeutics?
Incyte announced it has completed the acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The deal adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease, to Incyte’s hematology portfolio and late-stage development pipeline.
How much is Incyte paying for the Vega Therapeutics acquisition?
Incyte is paying $1.25 billion upfront to acquire all outstanding shares of Vega Therapeutics. Star Therapeutics is also eligible for up to an additional $750 million in sales milestone payments, tying part of the total consideration to future commercial performance.
What is VGA039 and how does it fit Incyte’s strategy?
VGA039 is an investigational monoclonal antibody in Phase 3 development for von Willebrand disease. It targets Protein S to improve hemostasis and is being developed as a once-monthly subcutaneous prophylactic therapy, aligning with Incyte’s focus on hematology and late-stage specialty medicines.
How will the Vega Therapeutics deal affect Incyte’s 2026 financials?
Incyte expects the transaction to be reflected as a one-time R&D expense in its third-quarter and full-year 2026 GAAP and non-GAAP financial results. This accounting treatment concentrates the upfront cost into 2026 reported earnings rather than spreading it over multiple years.
What regulatory designations has VGA039 received from the FDA?
VGA039 has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration. These designations can provide development support and potential review advantages, assuming the pivotal clinical data remain supportive.
How large is the von Willebrand disease population targeted by VGA039?
Approximately 135,000 people in the United States have been diagnosed with von Willebrand disease. VGA039 is being developed as a universal hemostatic therapy for all VWD types, aiming to simplify prophylaxis compared with frequent intravenous factor replacement infusions.